ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Abroad (travel likely)RecruitingPHASE2

Conditions

Gastrointestinal Stromal Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Miami, Miami, Florida, United States
Contact: Study coordinator (Leonela Wright) · lxw612@med.miami.edu · 305-243-0864
Contact: Study coordinator (Jonathan Trent, MD, PhD) · JTrent@med.miami.edu · 305-243-2581
Contact: Principal Investigator (Jonathan Trent, MD, PhD)

Study leads

Jonathan Trent, MD, PhD
Principal Investigator
University of Miami

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors · Metastatic Cancer

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Scottsdale, United States

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

Abroad (travel likely)Recruiting

Changsha, China

PH 2 Pemigatinib in SDH-deficient GIST

SDH Gene Mutation · Gastrointestinal Stromal Tumor

Abroad (travel likely)RecruitingPHASE2

Boston, United States

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Advanced Solid Tumours · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung

Abroad (travel likely)RecruitingPHASE1, PHASE2

London, United Kingdom · Manchester, United Kingdom